Core Insights - Pharvaris has published results from two Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, demonstrating the efficacy and safety of deucrictibant, a bradykinin B2 receptor antagonist, for managing hereditary angioedema (HAE) [1][2] Study Results - CHAPTER-1 study showed a statistically significant reduction in the occurrence of HAE attacks and improvements in disease control and health-related quality of life, with deucrictibant being well tolerated at both tested doses [3] - RAPIDe-1 study indicated a statistically significant reduction in the severity of HAE attack manifestations, along with reduced time to symptom relief and resolution, with deucrictibant well tolerated at all tested doses [4] Product Development - Deucrictibant is being developed in two formulations: an extended-release tablet for prophylactic treatment and an immediate-release capsule for on-demand treatment, aiming to provide a comprehensive approach to HAE management [8] - The company is preparing marketing authorization applications for the immediate-release capsule and is conducting a Phase 3 study (CHAPTER-3) for the extended-release tablet, with topline data expected in Q3 2026 [9] Industry Context - The use of bradykinin B2 receptor antagonism has been established as the standard-of-care for on-demand treatment of HAE attacks, with deucrictibant emerging as a potentially unique oral therapy for both prophylactic and acute treatment [5][2] - The concurrent publication of the study results in The Lancet Haematology adds to the scientific evidence supporting the management of bradykinin-mediated angioedema [5]

Summary of Pharvaris Conference Call Company Overview - **Company**: Pharvaris (NasdaqGS:PHVS) - **Focus**: Development of deucrictibant for treating Hereditary Angioedema (HAE) Recent Progress and Priorities - Pharvaris is preparing to file its first drug for acute treatment based on strong data from December 2025 - Ongoing prophy trial expected to have top-line readout in Q3 2026 - Enrollment in a pivotal trial for acquired angioedema is ongoing - Preparing for commercial launch and organizational ramp-up [4][11][19] Clinical Data Highlights - **RAPIDe-3 Trial Results**: - Primary endpoint (PGIC) achieved with deucrictibant relieving symptoms in approximately 1.28 hours compared to over 12 hours for placebo - New endpoint "End of Progression" showed patients stopped feeling worse in about 17.5 minutes - Complete symptom resolution achieved in less than 12 hours, outperforming standard care [8][9][10] Regulatory and Launch Preparations - NDA submission planned for the first half of 2026, with preparations on track - Pre-NDA meeting has already occurred, and the company is working towards a complete filing [11][13][17] Market Position and Strategy - The company anticipates a standard review from regulators, aiming for a potential launch in the first half of 2027 [17] - Emphasis on building visibility in the healthcare community through the "Deflate HAE" campaign to raise disease awareness [19][22] - The campaign aims to address the unmet need for effective treatments in the HAE patient community [22][24] Competitive Landscape - The oral on-demand treatment segment is expected to dominate, with a strong preference for oral therapies over injectables due to convenience [34][44] - The company believes that the profile of deucrictibant positions it favorably against existing treatments, particularly in terms of speed and efficacy [36][38] - There is a significant opportunity to switch patients from existing treatments to deucrictibant, especially as the oral segment grows [90][91] Prophylactic Opportunity - The CHAPTER-3 pivotal trial is progressing on track, with data expected in Q3 2026 [65] - The extended-release formulation is being developed alongside the immediate-release formulation, with distinct pharmacokinetic profiles [68][71] - The company aims for a broader label that includes normal C1 patients, addressing additional unmet medical needs [54][81] Financial Position - Cash balance reported at EUR 380 million as of Q3 2026, with a runway projected to the first half of 2027 [123] Conclusion - Pharvaris is strategically positioned to capitalize on the growing demand for oral therapies in the HAE market, with a strong focus on clinical data, regulatory preparations, and market awareness campaigns to support its upcoming product launches.

Summary of Pharvaris Conference Call Company Overview - **Company**: Pharvaris (NasdaqGS:PHVS) - **Industry**: Hereditary Angioedema (HAE) therapeutics - **Focus**: Development of therapies for bradykinin-mediated angioedema, including prophylactic and on-demand treatment options [1][2][3] Core Points and Arguments Market Evolution - The HAE market has evolved significantly over the past 20 years, transitioning from a focus on managing attacks to controlling the disease [8][9] - Current market size for on-demand treatment is estimated at **$600 million** in the US, representing about **20%** of the total HAE market [29][46] - The market is expected to be dominated by oral therapies due to their simplicity and speed of treatment [29][31] Product Development and Clinical Trials - Pharvaris is developing **deucrictibant**, with Phase 3 data showing statistically significant results across all primary and secondary endpoints [16][17] - Key Phase 3 endpoint results include: - Time to initial symptom relief: **1.28 hours** - Time to stop attack progression: **17.5 minutes** - Time to complete symptom resolution: less than **12 hours** [16][17] - The company is also conducting a Phase 3 trial for prophylactic treatment (CHAPTER-3) with top-line data expected in Q3 of this year [54][56] Patient Experience and Market Strategy - The convenience of an oral treatment is emphasized as a significant factor for patients, allowing for immediate use during an attack [20][22] - The company aims to provide a therapy that not only alleviates symptoms but also enhances the quality of life for patients [61] - Pharvaris is building awareness in the HAE community through campaigns like "Deflate HAE" and is preparing for product launches [52][100] Competitive Landscape - The current competitive landscape includes products like **icatibant** and **Orladeyo**, with Pharvaris aiming to offer a more effective oral alternative [28][46][49] - The company believes that a successful launch of deucrictibant could shift market dynamics, potentially leading to a return to branded pricing for on-demand treatments [48][49] Financial Position and Future Outlook - Pharvaris has a strong cash position with **EUR 360 million** reported in Q3, providing a runway into the first half of 2027 [107][108] - Upcoming catalysts include the NDA filing for on-demand treatment and the potential for a joint filing for prophylactic treatment [103][104] Additional Important Insights - The company is exploring opportunities in acquired angioedema, which is currently underdiagnosed and represents about **10%** of the market [71][75] - There is a strategic advantage in offering both on-demand and prophylactic options, allowing for flexibility in patient treatment plans [82][85] - The company is focused on building relationships with healthcare providers to facilitate the adoption of their therapies [100][101]

Summary of Pharvaris FY Conference Call Company Overview - **Company**: Pharvaris (NasdaqGS:PHVS) - **Focus**: Treatment of Hereditary Angioedema (HAE), a rare genetic condition characterized by painful and potentially fatal swelling attacks [4][5] Core Points and Arguments Company Background - Pharvaris was established 10 years ago, with a focus on addressing unmet needs in HAE treatment, particularly for an oral therapy option [4][6] - The company aims to develop deucrictibant, an oral B2 receptor antagonist, to provide a highly efficacious treatment for HAE and other forms of angioedema [7][8] Market Dynamics - The current market for HAE treatments is dominated by injectables, with approximately 63% of patients on long-term prophylaxis, representing about 80% of the market value [12][13] - The clinical guidelines suggest that ideally, HAE patients should never suffer from attacks, highlighting the need for effective prophylactic treatments [13] Clinical Data - The Phase 3 trial for deucrictibant in the on-demand setting showed significant results, with a primary endpoint met and all 11 secondary endpoints achieving statistical significance [16] - Key findings include: - Onset of symptom relief at 1.28 hours compared to 12 hours for placebo [17] - End of progression of the attack at 17 minutes, providing comfort to patients [17] - Faster complete resolution compared to standard care and recently approved oral therapies [19] Competitive Landscape - The oral therapy market is becoming increasingly competitive, with KalVista's EKTERLY recently launched. However, deucrictibant is positioned to differentiate itself through faster onset and resolution of symptoms [21][22] - The Phase 2 data for deucrictibant in the prophylactic setting showed an 84.5% attack reduction, comparable to injectable therapies [41] Regulatory and Commercial Strategy - Pharvaris plans to file for NDA in the first half of 2026, with a potential launch about a year later [20] - The company is expanding its Phase 3 studies to include a broader patient demographic and geographic range, which may mitigate risks associated with trial outcomes [45] Financial Outlook - The company has sufficient cash runway into the first half of 2027, with plans to ramp up commercial operations and team expansion [56][57] Additional Important Information - Pharvaris will present at the QUAD A conference, showcasing Phase 3 data and other significant findings, including a 92.3% attack reduction from an open-label extension study [53] - The company is also involved in community engagement, sponsoring events like the HAEA Foundation's 5K run [54] This summary encapsulates the key points discussed during the Pharvaris FY conference call, highlighting the company's strategic focus, clinical advancements, market positioning, and financial outlook.

Core Insights - Pharvaris is focused on developing oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases, particularly hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) [1][14] - The company outlined its strategic priorities for 2026, emphasizing long-term prophylaxis and on-demand treatment of HAE attacks [3][4] Clinical Development - The pivotal Phase 3 study, RAPIDe-3, demonstrated that deucrictibant significantly reduced the median time to onset of symptom relief to 1.28 hours compared to placebo (p<0.0001) [5] - Topline data from the CHAPTER-3 study, assessing deucrictibant for prophylactic treatment of HAE attacks, is expected in the third quarter of 2026 [4][5] - The NDA dossier for deucrictibant's on-demand treatment of HAE attacks is on track for filing in the first half of 2026 [4][5] Financial and Operational Updates - Pharvaris has an estimated cash runway into the first half of 2027, indicating strong financial management [4][11] - The company was added to the Nasdaq Biotechnology Index in December 2025, reflecting its compliance with market capitalization and trading volume requirements [11] Upcoming Events - Pharvaris will participate in several investor conferences and medical congresses in early 2026, showcasing its ongoing clinical studies and findings [8][10][12]

Core Insights - Pharvaris N.V. (NASDAQ:PHVS) is highlighted as a promising small-cap stock with significant upside potential, receiving a Buy rating from Morgan Stanley with a price target of $41 and an Outperform rating from Oppenheimer with a raised target of $50 from $44 [1][2]. Group 1: Clinical Study Results - The pivotal RAPIDe-3 study demonstrated positive top-line results for deucrictibant, confirming its potential for on-demand treatment of HAE attacks, with a median time to onset of symptom relief of 1.28 hours, significantly faster than placebo [2]. - All secondary efficacy endpoints were achieved, including a median End of Progression time of 17.47 minutes and complete symptom resolution in a median of 11.95 hours, confirming the safety profile of deucrictibant across various HAE subtypes and attack severities [3]. Group 2: Future Plans - Pharvaris N.V. plans to use data from the pivotal Phase 3 study as the basis for marketing authorization applications, which are expected to be filed in the first half of 2026 [4].

Investment Rating - The report maintains an investment rating of "Outperform" with a target price set for the leading stocks [7]. Core Insights - The National Healthcare Security Administration released the "Commercial Health Insurance Innovative Drug Directory (2025)", which includes 19 high-cost innovative drugs, including five CAR-T therapies and two Alzheimer's drugs. This is expected to improve payment difficulties for high-value innovative drugs and provide an additional payment pathway beyond basic medical insurance [3][24]. - The report highlights several promising stocks to watch, including those with high certainty for overseas expansion and those with potential overseas data catalysts [2][22]. Weekly New Drug Market Review - From December 1 to December 7, 2025, the new drug sector saw significant stock movements, with the top five gainers being Beihai Kangcheng (+13.94%), Maibo Pharmaceutical (+11.32%), Jiahe Biotech (+8.38%), Junsheng Tai (+7.14%), and Nuo Si Lan De (+6.27%). Conversely, the top five losers included Shengnuo Pharmaceutical (-15.18%), Shouyao Holdings (-9.06%), Boan Biotech (-8.62%), Tengsheng Bo Pharmaceutical (-8.05%), and Yiming Angke (-7.72%) [1][16]. New Drug Approval and Acceptance Status - This week, one new drug or new indication application was approved, and 16 new drug or new indication applications were accepted in the domestic market [4][28]. Clinical Application Approval and Acceptance Status - A total of 44 new drug clinical applications were approved, and 40 new drug clinical applications were accepted this week [5][31].

Core Insights - Pharvaris (PHVS) shares increased nearly 22% following positive results from the phase III RAPIDe-3 study for its drug deucrictibant, aimed at treating hereditary angioedema (HAE) attacks in adults and adolescents aged 12 and older [2][8] Study Results - The RAPIDe-3 study achieved its primary endpoint, with patients experiencing symptom relief within 1.28 hours after taking deucrictibant, compared to over 12 hours with placebo [3] - All secondary endpoints were met, including a median time to substantial symptom relief of under 3 hours with deucrictibant versus over 12 hours with placebo, and complete symptom resolution in 11.95 hours compared to more than 24 hours for placebo [3] - 83% of HAE attacks were managed with a single dose of deucrictibant, and over 93% of attacks were treated without the need for backup treatment [4] Regulatory Plans - Pharvaris plans to submit a regulatory filing for deucrictibant in the first half of 2026, which could position it as the second oral on-demand therapy for HAE after KalVista Pharmaceuticals' Ekterly [5] Competitive Landscape - Comparisons between deucrictibant and KalVista's Ekterly highlight potential advantages for deucrictibant, as it showed faster symptom relief in the RAPIDe-3 study compared to the KONFIDENT study supporting Ekterly's approval [6] - Year-to-date, Pharvaris stock has risen 53%, outperforming the industry growth of 20% [7] Product Development - Pharvaris is developing two formulations of deucrictibant: an immediate-release capsule for acute treatment and an extended-release tablet for prophylactic treatment [10] - The extended-release tablet is being evaluated in the phase III CHAPTER-3 study for HAE prophylaxis, with top-line data expected in the second half of 2026 [11] - Additionally, the extended-release formulation is under evaluation in the CREAATE study for treating acquired angioedema with C1-inhibitor deficiency [12] Market Positioning - If approved, deucrictibant will compete in the on-demand treatment space against KalVista's Ekterly, with advantages over older injectable treatments like Firazyr and Kalbitor due to its oral administration [14] - In the prophylactic treatment segment, competitors include BioCryst Pharmaceuticals and Ionis Pharmaceuticals, with BioCryst's Orladeyo and Ionis' Dawnzera being notable products [15]

Core Insights - Pharvaris N.V. announced topline data from the RAPIDe-3 Phase 3 trial of deucrictibant for treating hereditary angioedema (HAE) attacks, indicating positive results for the on-demand treatment [1][3] Study Results - The RAPIDe-3 trial enrolled 134 participants aged 12 years and older, evaluating the oral deucrictibant immediate-release (IR) capsule for HAE attacks [2] - Deucrictibant showed a faster median time to treatment response compared to placebo, with shorter median times for substantial symptom relief and complete symptom resolution [3] - The data indicated fewer attacks required a second dose or rescue medication within 12 hours [4] - 83.0% of attacks were treated with a single capsule of deucrictibant IR, and 93.2% of treated attacks did not require rescue medication [9] Safety and Tolerability - Deucrictibant was well tolerated, with no serious treatment-related adverse events reported, and no participants discontinued treatment due to adverse events [5] Future Plans - The data from the RAPIDe-3 study will support marketing authorization applications planned for submission in the first half of 2026 [3] Competitive Landscape - The FDA approved Ionis Pharmaceuticals' Dawnzera for HAE prophylaxis, which significantly reduced the monthly attack rate by 81% compared to placebo over 24 weeks [6] - KalVista Pharmaceuticals' Ekterly was also approved for acute HAE attacks, being the first oral on-demand treatment for HAE [7] Market Reaction - Pharvaris shares increased by 12.32% to $27.09 following the announcement of the trial results [7]

Core Insights - Pharvaris announced pivotal data from the RAPIDe-3 study, confirming the efficacy of deucrictibant for on-demand treatment of hereditary angioedema (HAE) attacks, with plans for marketing authorization applications in the first half of 2026 [1][7] Study Design and Results - The RAPIDe-3 study was a global Phase 3, placebo-controlled trial involving 134 participants from 24 countries, assessing the immediate-release (IR) capsule of deucrictibant (20 mg) for HAE treatment [2] - The study achieved statistical significance for the primary endpoint and all 11 secondary efficacy endpoints, making it the first on-demand HAE study compliant with the Core Outcome Set recommended in the AURORA consensus [2][3] Efficacy and Safety - Deucrictibant demonstrated a median time to onset of symptom relief of 1.28 hours, significantly faster than placebo (p<0.0001) [3][4] - All secondary efficacy endpoints were met, including a median time to End of Progression™ of 17.47 minutes and complete symptom resolution in 11.95 hours [3][4] - The safety profile of deucrictibant was well-tolerated, with no serious adverse events reported [5][9] Future Plans - Pharvaris is preparing to submit a New Drug Application (NDA) to the FDA in the first half of 2026 for deucrictibant as an on-demand treatment for HAE attacks [7][10] - An ongoing open-label extension study (RAPIDe-2 Part B) will provide additional efficacy and safety data [7] Company Overview - Pharvaris is focused on developing oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated conditions, including HAE [10] - The company aims to provide therapies that combine injectable-like efficacy with the convenience of oral administration [10]